

Updates to FDA Forms 356h & 1571:

Commercial vs. Research SNOMED CT Combination Products





Part I

- Review of the following updates to forms 356h & 1571:
 - Commercial vs. Research
 - SNOMED CT
 - Combination Products

Part II

LIVE walk-through of forms 356h &
 1571 with mock data

Part III

- Contact Information
- Acknowledgments



Mia Prather

Supervisory Program Analyst
Office of Business Informatics (OBI)
Division of Data Management Services & Solutions
Center for Drug Evaluation and Research
U.S. Food and Drug Administration





Beginning May 5, 2018, Commercial INDs will be required in eCTD format.

The latest fillable Form FDA 1571, found on the FDA Forms Website, allows the submitter to identify an IND submission as either Commercial or Research.

Where will it be on the form?

The new identifier is located in field 6B.

6A.	IND	Number	· (It	f previously as	ssi	gned)
6B.	Sele	ct One:		Commercial		
				Research		
				Research		



How will I obtain this information so I can successfully complete the form?

Select Commercial (IND) if the product under investigation is intended to be commercialized at a later date.

OR

✓ Select Research (IND) if the product under investigation is not intended to be commercialized at a later date.

Note: Instructions for completing the form can be found on the FDA's Forms website: https://www.fda.gov/AboutFDA/ReportsManualsForms/Forms/ListFormsNumerically/default.htm



Who do I contact if I have questions?

For further questions, please contact:

CDER Division of Drug Information U.S. Food and Drug Administration druginfo@fda.hhs.gov

Tel: 855-543-3784 or 301-796-3400

Fax: 301-431-6353



SNOMED CT

Leposava Antonovic, PhD

Science Policy Analyst

Office of New Drugs (OND) – Immediate Office (IO)

Center for Drug Evaluation and Research

U.S. Food and Drug Administration

SNOMED CT in FDA 1571 and FDA 356h Forms What is SNOMED CT and why is it being implemented?




- SNOMED CT stands for <u>Systematized Nomenclature of</u> <u>Medicine Clinical Terms.</u>
- The most comprehensive clinical healthcare terminology in the world with more than 30 countries actively contributing to its development and maintenance.
- Supported by National Library of Medicine (NLM), Center for Disease Control (CDC) and Prevention and the Office of the National Coordinator (ONC) for Health Information Technology.
- Required FDA terminology standard for coding study data indications of the IND, NDA, BLA and ANDA submissions.
- Additional tracking and metrics analysis.

SNOMED CT in FDA 1571 and FDA 356h Forms Where are the changes located on the Forms?




• Form 1571:

- Field 7 changed to 7A
- Field 7B added to capture the SNOMED CT Indication Disease Term



Form 356h:

- Field 15 changed to 15A
- Field 15B added to capture the SNOMED CT Indication Disease Term



SNOMED CT in FDA 1571 and FDA 356h Forms How will I get SNOMED CT information?




- Navigate to http://browser.ihtsdotools.org/
- Make sure to select **US Edition** extension.
- Instructions on how to fill out Forms FDA 1571 and FDA 356h may be found at

https://www.fda.gov/AboutFDA/ReportsManualsForms/ Forms/ListFormsNumerically/default.htm


SNOMED CT in FDA 1571 and FDA 356h Forms How will I get SNOMED CT information? *Cont.*





SNOMED CT in FDA 1571 and FDA 356h Forms How will I get SNOMED CT information? *Cont.*





SNOMED CT in FDA 1571 and FDA 356h Forms How do I enter SNOMED CT information?



Example: 38341003 | Hypertensive disorder, systemic arterial (disorder) |

•	Form	FDΔ	1571
_			

7A. (Proposed) Indication for Use For the treatment of hypertension, to lower the	Is this indication for a rare disease (prevalence <200,000 in U.S.)?				
blood pressure.	Does this product have an FDA Orphan Designation for this indication? Yes No If yes, provide the Orphan Designation number for this indication: Continuation Page for #7				
7B. SNOMED CT Indication Disease Term (Use continuo 38341003 Hypertensive disorder, systemic arteri	uation page for each additional indication and respective coded disease term) al (disorder)				

Form FDA 356h

15A. Proposed Indication for Use For the treatment of hypertension, to lower the blood pressure.	Is this indication for a rare disease (prevalence <200,000 in U.S.)?				
	Does this product have an FDA Orphan Designation for this indication? Yes No	If yes, provide the Orphan Designation number for this indication:	Continuation Page for #15		
15B. SNOMED CT Indication Disease Term (Use continued)	ation page for each additional indication	on and respective coded disease	term)		
38341003 Hypertensive disorder, systemic arterial	(disorder)	331			

FAQs: Do I need to provide SNOMED CT code for every proposed indication?




- Yes. A single SNOMED CT coded disease term (Concept ID and Concept Term) should be provided for each proposed indication.
- Consistent with the instructions for the Proposed Indication for Use; the Continuation Page should be used if there are more than one proposed indication and respective SNOMED CT Indication Disease Term per entry.

FAQs: How do I submit multiple indications and respective SNOMED CT codes?




Form 1571:

 Use the "Continuation Page for #7" button located in this field to provide additional indications and respective SNOMED CT codes.



Form 356h:

 Use the "Continuation Page for #15" button located in this field to provide additional indications and respective SNOMED CT codes.



FAQs: When are new versions of SNOMED CT US Edition released?



- New versions of SNOMED CT US Edition are generally available in March and September of each year.
- http://browser.ihtsdotools.org/

FAQs: Do I need to update SNOMED CT coded disease terms when a new version is released?




- In cases where SNOMED CT coded indication disease term(s) for given application/submission have changed, the updated SNOMED CT coded indication disease term(s) should be provided.
- The updated information should be provided with next additional information or supplement submission.

FAQs: What should I do if I cannot find the Target Disease I am looking for?



- SNOMED CT terminology can have multiple levels of "granularity". Some indication disease terms may be high level terms (low granularity) while some may be low level terms (high granularity).
- Use the lowest level (high granularity) term as possible.



38341003 | Hypertensive disorder, systemic arterial (disorder) |

71701000119105 | Hypertension in chronic kidney disease due to type 1 diabetes mellitus (disorder) |

140131000119102 | Hypertension in chronic kidney disease stage 2 due to type 2 diabetes mellitus (disorder) |

FAQs:

Who do I contact if I have questions?



For further questions, please contact:

CDER Division of Drug Information U.S. Food and Drug Administration druginfo@fda.hhs.gov

Tel: 855-543-3784 or 301-796-3400

Fax: 301-431-6353



Combination Products

Melissa Burns

Senior Program Manager
CAPT, US Public Health Service
Office of Combination Products
Office of Special Medical Programs
U.S. Food and Drug Administration



What is a Combination Product?

- A "combination product" is:
 - A product comprised of two or more different types of medical products (e.g., drug and device, drug and biological product, device and biological product, or all three together)
- Combination Products are assigned to a "Lead Center" having primary responsibility for their review (e.g., either CBER or CDER for companies submitting NDA/BLA/ANDA/IND)









What is NOT a combination product?

- A combination product is *NOT*:
 - A product comprised of only two or more of the same type of medical product (e.g., drug and drug, device and device, or biologic and biologic).
 - A medical product combined *only* with a non-medical product (e.g., drug and food, drug and cosmetic). See 21 USC 353(g).
- The following <u>ARE NOT</u> combination products:
 - Drugs combined only with each other, such as fixed dose combination drugs
 - Kits of JUST devices, JUST drugs, or JUST biological products
 - Separately distributed general use delivery devices (e.g. syringes) and drugs or biologics with which they can be used.



Categories of Combination Products

	"Single-entity"	"Co-packaged"	"Cross-labeled"
Description	Chemically or physically combined constituent parts	Constituent parts packaged together	Constituent parts that are packaged separately, but labeled and need to be used specifically with one another to achieve the intended therapeutic effect
Examples	Prefilled syringeTransdermal patchDrug-eluting stent	 First-aid or surgical kit Syringe packaged with vial of drug Drug + prefilled diluent, reconstitution/ transfer device, fillable cartridge and wearable patch 	 Some light activated drug product packaged separately from the light activation device
Reference	21 CFR 3.2(e)(1)	21 CFR 3.2(e)(2)	21 CFR 3.2(e)(3) and 21 CFR 3.2(e)(4)



Types of Combination Products

Type	Description	Common Example(s)
1	Convenience Kit or Co-Package Drug and device are provided as individual constituent parts within the same package	Drug or biological product vials packaged with device or accessory kits (empty syringes, autoinjectors, transfer sets)
2	Prefilled Drug Delivery Device/ System Drug is filled into or otherwise combined with	Prefilled drug syringe, auto-injectors, metered- dose inhalers, dry power inhalers, nasal-spray, pumps or spray bottles, transdermal patches,
	the device AND the sole purpose of the device is to deliver drug	prefilled iontophoresis system or microneedle patch
3	Prefilled Biologic Delivery Device/ System Biological product is filled into or otherwise combined with the device AND the sole purpose of the device is to deliver biological product	Prefilled vaccine or other biological product syringes, autoinjectors, nasal Sprays, dropper bottles, transdermal or microneedle patches pre-coated with biological product
4	Device Coated/ Impregnated/ Otherwise Combined with Drug Device has an additional function in addition to delivering the drug	Drug pills embedded with sensors, contact lens coated with a drug



Types of Combination Products

Type	Description	Common Example(s)
5	Device Coated or Otherwise Combined with Biologic Device has an additional function in addition	Live cells seeded on a device scaffold
6	to delivering the drug Drug/Biologic Combination	Antibody drug conjugatos
0	<u>. </u>	Antibody-drug conjugates
7	Separate Products Requiring Cross Labeling	Light-activated drugs or biological products labeled for use with a specific light-activation device
8	Possible Combination Based on Cross Labeling of Separate Products	Drug/biological product labeling discusses a device, but submitter is unsure whether the product constitutes a cross-labeled combination product
9	Other Type of Part 3 Combination Product (e.g., Drug/Device/ Biological Product)	Combination product not otherwise described above All 3 articles are combined in a single product (e.g., a prefilled syringe containing an antibody-
		drug conjugate)



Request for Designation (RFD)

- An RFD is a written submission to the Office of Combination Products (OCP) that request a determination of:
 - The regulatory identity or classification of a product as a drug, device, biological product, or combination product, and/or
 - The component of FDA that will regulate the product if it is a noncombination product or which Center (CBER/CDER/CDRH) will have primary jurisdiction for premarket review and regulation if it is a combination product.
- Most products do not require an RFD prior to making a premarket submission
 - Submission of an RFD is generally only needed when the classification of a product or the Center to which it should be assigned is unclear or in dispute.



How do I know if my Product is a Combination Product and/or What Type of Combination Product?

- In many cases, FDA will have identified the product as a combination product during meeting and submission interactions.
- Use the examples provided in the previous slides as references.
- For marketed products, the combination product identifiers are also used for Registration and Listing (check your R&L).
- If you are still unsure, contact the Lead Center for assistance:
 - CDER: <u>CDERProductJurisdiction@fda.hhs.gov</u>
 - CBER: CBERProductJurisdition@fda.hhs.gov



Why do I Need to Include Combination Product Information on the 356h and 1571 Forms?

- Combination products typically require consults and collaboration between multiple FDA Medical Product Centers (CBER, CDER, CDRH)
 - Early identification of submissions for combination products helps ensure appropriate expertise is engaged early and that Sponsors receive timely and comprehensive review of their submissions
- Congress recognized the importance of Sponsor's identifying their products as combination products when interacting with FDA
 - See Section 3038 of the <u>21st Century Cures Act</u>: "In seeking agency action with respect to a combination product, the sponsor of such product—shall identify the product as a combination product."
 - Use of the combination product fields on FDA 356h and 1571 enables
 Sponsors to fulfill this requirement



When do I Need to Enter Combination Product Information on the 356h and 1571 Form?

- The Sponsor selects "Yes" or "No" that the product is a combination product for submissions that are:
 - For 356h: NDA/ANDA/BLA Originals or Supplements (Labeling, CMC, Efficacy, or REMS)
 - For 1571: IND Originals
- If the product is NOT a combination product (e.g., "No" is selected) the Combination Product Type field is not required (leave blank)
- If the product IS a combination product (e.g., "Yes" is selected) a single-digit numeric representing the combination product type is entered into the Combination Product Type field
- If a Request for Designation has been submitted for the product in the submission, the RFD number (six-digit numeric) is entered in the RFD field



Where do I Enter Combination Product Information on the 356h and 1571 Form?

The combination product fields are located at:

Form 356h: Field 24

	очь-турс	☐ Initial Submission	Resubmission	the appropriate cate;	CBE-30
24		s and all Supplements, is the product (21 CFR 3.2(e)?		Combination Product Type (See instructions)	Request for Designation (RFD) Number
25	Does the sul	omission contain:	Human factors inform	nation? 26. Proposed Marketing	Status (Select one)

Form 1571: Field 12

Protocol			ispute Resolution	
12. For Originals, is the product a combination product (21 CFR 3.2(e))?	Yes No	Combination Product Type (See instructions)	Request for Designation (RFD) Number	

13. Select the following only if applicable. (Justification statement must be submitted with application for any items selected below.



Where Can I find Additional Information on Combination Products?

 Visit the Office of Combination Products Frequently Asked Questions webpage:

https://www.fda.gov/CombinationProducts/AboutCombinationProducts/

 If you still have questions, contact the Lead Center or the Office of Combination Products (OCP) for assistance:

CDER: CDERProductJurisdiction@fda.hhs.gov

– CBER: CBERProductJurisdition@fda.hhs.gov

– OCP: <u>combination@fda.gov</u>



of Forms 356h & 1571 with mock data

Elizabeth Chen, PharmD

Science Policy Analyst
Office of New Drugs (OND) – Immediate Office (IO)
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

For More Information



FDA Forms Webpage

https://www.fda.gov/AboutFDA/ReportsManualsForms/Forms/ListFormsNumerically/default.htm

CDER Division of Drug Information

U.S. Food and Drug Administration druginfo@fda.hhs.gov

Tel: 855-543-3784 or 301-796-3400

Fax: 301-431-6353



Thank You!

(In Alphabetical Order)

- Members of the FDA Forms Working Group
- Terry Artman
- Sonja Brajovic
- Eric Brodsky
- Cherryn Chang
- Gregory Chin
- Ishani Chowdhury
- Marc Cohen
- Danita Dixon
- Ronald Fitzmartin

- Fatima Frye
- William Hess
- Virginia Hussong
- Karina Kuhn
- Sherry Lard
- Kristina Lauritsen
- Christopher Leptak
- Mary Ann Slack
- Carla Vincent